Allurion Technologies Inc. (ALUR)
NYSE: ALUR · Real-Time Price · USD
1.700
-0.010 (-0.58%)
At close: Dec 5, 2025, 4:00 PM EST
1.710
+0.010 (0.59%)
After-hours: Dec 5, 2025, 7:28 PM EST
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Shantanu Gaur |
Contact Details
Address: 11 Huron Drive Natick, Massachusetts 01760 United States | |
| Phone | 508 647 4000 |
| Website | allurion.com |
Stock Details
| Ticker Symbol | ALUR |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1964979 |
| CUSIP Number | 02008G102 |
| ISIN Number | US02008G2012 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President, Principal Financial and Accounting Officer and Director |
| Ojas A. Buch | Chief Operating Officer |
| Brendan Michael Gibbons J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Samuel G. Levy | Co-Founder |
| Dr. Ram Chuttani M.D. | MD, Chief Medical Officer and Founding Partner |
| Alexandra van der Stap | Vice President of Global Marketing |
| Laurent Laffineur | Vice President of International Sales and Marketing |
| Matt Wright | Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2025 | 144 | Filing |
| Nov 26, 2025 | D | Notice of Exempt Offering of Securities |
| Nov 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 24, 2025 | ARS | Filing |
| Nov 24, 2025 | DEF 14A | Other definitive proxy statements |
| Nov 18, 2025 | 424B3 | Prospectus |
| Nov 18, 2025 | 424B3 | Prospectus |
| Nov 17, 2025 | 10-Q | Quarterly Report |
| Nov 17, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 14, 2025 | PRE 14A | Other preliminary proxy statements |